Skip to content
← Lobby Directory
SM
NGOScanBalt

ScanBalt MTÜ

Tartu, ESTONIAMTÜReg: 537040240933-13Since 14/01/2021

Budget

€25 — €0

EP Access

0

accredited persons

Staff

2

0.5 FTE

EU Grants

None

Mission & Goals

ScanBalt is an innovation network that brings together academic and industrial research, university hospitals and non-university research institutions, study centres and highly specialised suppliers in the pharmaceutical, biotechnology and medical technology sectors from different European countries and regions.

EU Legislative Interests

AI Act Artificial Intelligence is rapidly transforming healthcare, diagnostics, drug discovery, and personalised medicine - all core domains of ScanBalt’s community. The AI Act will shape how AI systems are developed, validated, and deployed within Europe. ScanBalt is particularly interested in: Ensuring innovation-friendly regulation that supports SMEs and research-driven innovators Clarifying requirements for high-risk medical AI systems Supporting trust, safety, and ethical AI adoption in health and life sciences Avoiding unnecessary regulatory burdens that could slow European competitiveness Given the strong presence of digital health and AI-driven companies within our network, this regulation directly affects our members’ ability to innovate and scale. Bioproduction Bioproduction is a strategic pillar for Europe’s future resilience, sustainability, and technological sovereignty. It underpins pharmaceuticals, advanced therapies, biomaterials, industrial biotechnology, and circular bioeconomy solutions. ScanBalt’s interest stems from: The Baltic Sea Region’s strengths in biotechnology, biomanufacturing, and bio-innovation The need to strengthen European biomanufacturing capacity and value chains Opportunities for sustainable and green production technologies Supporting scale-up pathways for biotech SMEs and startups Bioproduction policies directly influence investment, infrastructure development, skills, and cross-border collaboration - all key priorities for ScanBalt. European Health Data Space (EHDS) Data is foundational for modern healthcare innovation, research, and AI development. The EHDS has the potential to significantly enhance cross-border research, clinical innovation, and patient-centric digital services. ScanBalt closely follows EHDS developments due to: Its impact on health data access, sharing, and secondary use The importance of interoperability across EU member states Enabling AI, precision medicine, and real-world evidence generation Balancing data protection, innovation, and public trust Many ScanBalt members rely on secure, lawful, and efficient data ecosystems for research, product development, and healthcare solutions.

Communication Activities

ScanBalt Forum 2020 in the framework of Germany EU Presidency 2020: https://scanbalt.org/european_common_dataspace/. ScanBalt presented the comments on the EC EHDS proposal in June 2022 during the French EU Council presidency (https://scanbalt.org/support-the-declaration-eu-health-data-space/). ScanBalt is currently preparing the next package of proposals to be presented in May 2025. .

Interests Represented

Promotes their own interests or the collective interests of their members

Organisation Members

https://scanbalt.org/members/

Commissioner Meetings

No recorded meetings with EU commissioners.